Eledon Pharmaceuticals (ELDN) Shares Outstanding (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Shares Outstanding data on file, last reported at $75.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 26.67% year-over-year to $75.9 million; the trailing twelve-month figure through Mar 2026 stood at $75.9 million (up 26.67% YoY), and the FY2025 full-year result was $75.4 million, up 26.16% from the prior year.
• Shares Outstanding for Q1 2026 stood at $75.9 million, up from $75.4 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $75.9 million in Q1 2026 and bottomed at $6204.0 in Q1 2022.
• The 5-year median for Shares Outstanding is $24.2 million (2023), against an average of $33.4 million.
• The widest annual swing landed in 2022, when Shares Outstanding sank 99.96%; it then soared 399853.74% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $13.8 million in 2022, then jumped by 75.75% to $24.2 million in 2023, then surged by 146.93% to $59.8 million in 2024, then climbed by 26.16% to $75.4 million in 2025, then climbed by 0.56% to $75.9 million in 2026.
• The last three Shares Outstanding figures came in at $75.9 million (Q1 2026), $75.4 million (Q4 2025), and $59.9 million (Q3 2025), per Business Quant data.

Peer Comparison